Gísli Jenkins

Advances in Extracellular Matrix-Associated Diagnostics and Therapeutics

Rare variants and survival of patients with idiopathic pulmonary fibrosis: analysis of a multicentre, observational cohort study with independent validation

Impact of Environmental Exposures on the Development and Progression of Fibrotic Interstitial Lung Disease

Lower Airway and Oral Microbiome Dysbiosis in Patients with Long COVID Post-Hospitalisation: A UK Multicentre, Prospective Cohort Study

Imperfect wound healing sets the stage for chronic diseases

Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial

Zinpentraxin Alfa for Idiopathic Pulmonary Fibrosis: The Randomized Phase III STARSCAPE Trial

Cluster analysis of blood biomarkers to identify molecular patterns in pulmonary fibrosis: assessment of a multicentre, prospective, observational cohort with independent validation

The fibroblast hormone Endotrophin is a biomarker of mortality in chronic diseases

Phase 2, Double-Blind, Placebo-controlled Trial of a c-Jun N-Terminal Kinase Inhibitor in Idiopathic Pulmonary Fibrosis

Adaptive multi-interventional trial platform to improve patient care for fibrotic interstitial lung diseases

Corticosteroid therapy in fibrotic interstitial lung disease: a modified Delphi survey

1-year health outcomes associated with systemic corticosteroids for COVID-19: a longitudinal cohort study

Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis Is Associated with Common Genetic Variants and Limited Rare Variants

PCSK6 and Survival in Idiopathic Pulmonary Fibrosis

Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study

Systemic corticosteroids in fibrotic lung disease: a systematic review and meta-analysis

Cohort Profile: Post-Hospitalisation COVID-19 (PHOSP-COVID) study

Pulmonary Fibrosis Stakeholder Summit: A Joint NHLBI, Three Lakes Foundation, and Pulmonary Fibrosis Foundation Workshop Report

Cohort Profile: Post-hospitalisation COVID-19 study (PHOSP-COVID)

One year health outcomes associated with systemic corticosteroids for COVID-19: a longitudinal cohort study

Parenchymal lung abnormalities following hospitalisation for COVID-19 and viral pneumonitis: a systematic review and meta-analysis

A lung targeted miR-29 mimic as a therapy for pulmonary fibrosis

Longitudinal lung function and gas transfer in individuals with idiopathic pulmonary fibrosis: a genome-wide association study

Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial

Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective

Characteristics and risk factors for post-COVID-19 breathlessness after hospitalisation for COVID-19

Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study

Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19